secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001193125-25-241951
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio reports long-term Phase 1b data for budoprutug; up to 3-year proteinuria control
--------------------------------------------------------------------------------

- Abstract published for budoprutug (anti-CD19 mAb) showing durable proteinuria control up to 3 years in four PMN patients.
- Three of four patients required no further immunosuppressive treatment after up to 4 doses.
- No treatment-related adverse events grade 3 or higher observed in the Phase 1b trial (NCT04652570).
- Data support continued development of budoprutug for B-cell mediated diseases.
- Company remains focused on advancing its pipeline; risks include clinical and regulatory uncertainties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525241951/0001193125-25-241951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525241951/d34212d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-241951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer